argenx SE (ARGX)
| Market Cap | 49.41B +2.8% |
| Revenue (ttm) | 5.32B +70.3% |
| Net Income | 1.72B +33.9% |
| EPS | 26.21 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 28.81 |
| Forward PE | 26.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,475,063 |
| Open | 831.23 |
| Previous Close | 928.44 |
| Day's Range | 787.73 - 832.24 |
| 52-Week Range | 661.85 - 1,072.75 |
| Beta | -0.03 |
| Analysts | Buy |
| Price Target | 1,170.57 (+42.99%) |
| Earnings Date | Oct 22, 2026 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price target is $1,170.57, which is an increase of 42.99% from the latest price.
News
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation.
Argenx has ‘good news and bad news’ day, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao says Argenx (ARGX) is having a “good news and bad news” day. The company announced positive topline results from the 126-patient Phase 2 FB102 study…
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Argenx said on Thursday it had discontinued a late-stage study of its efgartigimod drug in adults with Sjögren's disease, an autoimmune condition that damages the glands producing tears and saliva, ...
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
Argenx to discontinue UNITY study of efgartigimod subcutaneous
Argenx (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous, or SC, in adults with moderate-to-severe Sjogren’s disease. The decision is based on the recommen...
Argenx announces FB102 study met its primary endpoint
Argenx (ARGX) announced topline results from the Phase 2 study evaluating FB102, a CD122 inhibitor, in adults with celiac disease. These results represent the first clinical readout of FB102 following...
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study ...
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celi...
Halozyme, Argenx Expand ENHANZE Collaboration With Two Additional Targets
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) announced an expansion of its global collaboration with argenx SE(ARGX), granting the company exclusive access to its ENHANZE drug-delivery technology fo...
Halozyme expands global collaboration and license agreement with Argenx
Halozyme Therapeutics (HALO) announced that it has expanded its global collaboration and license agreement with Argenx (ARGX) to develop and commercialize ENHANZE with two additional exclusive targets...
BMY or ARGX: Which Is the Better Value Stock Right Now?
BMY vs. ARGX: Which Stock Is the Better Value Option?
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
Wall Street is overwhelmingly bullish about Argenx. Analysts like the growth driven by the company's Vyvgart franchise and its promising pipeline.
Argenx To Present New VYVGART Data Across Autoimmune Neuromuscular Disorder At AANEM & MGF Session
(RTTNews) - On Tuesday, Argenx SE (ARGX) announced that it will present new clinical, long-term and real-world data for VYVGART (efgartigimod) across Myasthenia gravis and Chronic inflammatory demyeli...
Argenx to present new data across its portfolio, pipeline at 2026 AANEM
argenx (ARGX) will present new data from across its portfolio and pipeline at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine, AANEM, Annual Meeting and the Myasthenia Grav...
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from mo...
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months
Argenx's Vyvgart franchise enjoys strong sales momentum. The company has multiple registrational data read-outs on the way.
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.
Wells Fargo and UBS have 12-month price targets for Argenx that are more than 40% above the current share price. Argenx's momentum and clinical successes appear to justify these lofty expectations.
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meet...
argenx SE at Morgan Stanley Global Healthcare Conference Transcript
argenx SE at Morgan Stanley Global Healthcare Conference Transcript
argenx SE Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China innovation and AI integration are expanding opportunities, while MG and CIDP drive strong growth with new label expansions. The pipeline is robust, with key catalysts ahead in IMNM, MMN, and celiac, and a vision to reach 50,000 patients and 10 indications by 2030.
argenx SE Transcript: Wells Fargo 21st Annual Healthcare Conference
Vision 2030 targets treating 50,000 patients and 10 diseases, with strong progress in MG, CIDP, and pipeline expansion. VYVGART leads in MG and CIDP, while empasiprubart and FB102 target white space indications. Next-gen FcRn and a broad immunology focus support long-term growth.
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovatio...